Table 3.
Emetogenic potential of single intravenous antineoplastic agents
| High | Anthracycline/cyclophosphamide combinationa | |
| Carmustine | ||
| Chlormethine (mechlorethamine) | ||
| Cisplatin | ||
| Cyclophosphamide ≥1500 mg/m2 | ||
| Dacarbazine | ||
| Streptozocin | ||
| Moderate | Alemtuzumab | |
| Arsenic trioxide | Idarubicin | |
| Azacitidine | Ifosfamide | |
| Bendamustine | Irinotecan | |
| Busulfan | Irinotecan peg-liposomal | |
| Carboplatinb | Lurbinectedin | |
| Clofarabine | Naxitamab | |
| Cyclophosphamide <1500 mg/m2 | Oxaliplatin | |
| Cytarabine >1000 mg/m2 | Romidepsin | |
| Cytarabine/daunorubicin liposomal | Sacituzumab–govitecanc | |
| Daunorubicin | Temozolomided | |
| Dinutuximab beta | Thiotepae | |
| Doxorubicin | Trabectedin | |
| Epirubicin | Trastuzumab-deruxtecanc | |
| Low | Aflibercept | Ixabepilone |
| Amivantamab | Loncastuximab–tesirine | |
| Axicabtagene–ciloleucel | Margetuximab | |
| Belinostat | Melphalan–flufenamide | |
| Blinatumomab | Methotrexate | |
| Bortezomib | Mirvetuximab–soravtansine | |
| Brentuximab–vedotin | Mitomycin | |
| Cabazitaxel | Mitoxantrone | |
| Carfilzomib | Moxetumomab–pasudotox | |
| Catumaxomab | Necitumumab | |
| Cetuximab | Nelarabine | |
| Copanlisib | Paclitaxel | |
| Cytarabine ≤1000 mg/m2 | Paclitaxel nab-albumin | |
| Decitabine | Panitumumab | |
| Docetaxel | Pemetrexed | |
| Doxorubicin peg-liposomal | Pertuzumab | |
| Elotuzumab | Tafasitamab | |
| Enfortumab–vedotin | Tagraxofusp | |
| Eribulin | Teclistamab | |
| Etoposide | Temsirolimus | |
| 5-Fluorouracil | Tisagenlecleucel | |
| Gemcitabine | Tisotumab–vedotin | |
| Gemtuzumab–ozogamicin | Topotecan | |
| Inotuzumab–ozogamicin | Trastuzumab–emtansine | |
| Isatuximab | Vinflunine | |
| Minimal | Asparaginase (calaspargase pegol) | |
| Atezolizumab | Nivolumab | |
| Avelumab | Obinutuzumab | |
| Belantamab–mafodotin | Ofatumumab | |
| Bevacizumab | Pembrolizumab | |
| Bleomycin | Pixantrone | |
| Cemiplimab | Polatuzumab–vedotin | |
| Cladribine (2-chlorodeoxyadenosine) | Pralatrexate | |
| Daratumumab | Ramucirumab | |
| Dostarlimab | Rituximab | |
| Durvalumab | Trastuzumab | |
| Emapalumab | Tremelimumab | |
| Fludarabine | Vinblastine | |
| Ipilimumab | Vincristine | |
| Mosunetuzumab | Vinorelbine | |
a
The combination of an anthracycline and cyclophosphamide in patients with breast cancer is highly emetogenic.
b
Emetic potential appears to be at the high end of the moderate category.
c
Emetic potential appears to be at the high end of the moderate category, most closely resembling that of carboplatin.
d
No direct evidence found for temozolomide intravenous; as all sources indicate a similar safety profile of oral temozolomide, the classification was based on oral temozolomide.
e
Classification refers to individual evidence from paediatric trials.